// App-Quantinova.ai

S208 : EFFICACY AND SAFETY OF ZANDELISIB ADMINISTERED BY INTERMITTENT DOSING (ID) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA: PRIMARY ANALYSIS OF THE GLOBAL PHASE 2 STUDY TIDAL

Researchers

Presenter

  • Andrew Zelenetz

Principal Investigators

  • Wojciech Jurczak

  • Vincent Ribrag

  • Kim Linton

  • Graham Collins

  • Javier Lopz-Jimnez

  • Nishitha Reddy

  • Andrea Mengarelli

  • Tycel Phillips

  • Gerardo Musuraca

  • Oonagh Sheehy

  • Joanne Li

  • Weiming Xu

  • Michel Azoulay

  • Richard Ghalie

  • Pier Luigi Zinzani

Medical Centers

  • Institut Gustave Roussy,Villejuif,Франция

  • Vanderbilt University Cancer Center,Nashville, TN,Verenigde Staten

  • Kyowa Kirin Co.,Princeton,Vereinigte Staaten

  • Kyowa Kirin Co.,Princeton,États-unis

  • Vanderbilt University, Nashville, Tennessee, United States

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • GenesisCare,Oxford,Vereinigtes Königreich

  • Regina Elena National Cancer Institute, Rome, Italy

  • Institut Gustave-Roussy, Villejuif, France

  • Memorial Sloan Kettering Cancer Center,New York ,États-unis

  • Manchester Cancer Research Centre,Manchester,Vereinigtes Königreich

  • Manchester Cancer Research Centre, Manchester, United Kingdom

  • Institut Gustave-Roussy, Villejuif, France

  • Manchester Cancer Research Centre,Manchester,Vereinigtes Königreich

  • Regina Elena National Cancer Institute, Rome, Italy

  • University of Michigan Health Systems,

  • Regina Elena National Cancer Institute, Rome, Italy

  • Memorial Sloan Kettering Cancer Institute,New Yor

  • Kyowa Kirin Co.,Princeton,Stati Uniti

  • Belfast Health and Social Care Trust,Belfast,Verenigd Koninkrijk

  • Memorial Sloan Kettering Cancer Center,New York,Vereinigte Staaten

  • Memorial Sloan Kettering Cancer Institute,New York City,États-unis

  • Kyowa Kirin Co.,Princeton,Estados Unidos

  • GenesisCare,Oxford,Royaume-uni

  • Memorial Sloan Kettering Cancer Institute,New York City,États-unis

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Memorial Sloan Kettering Cancer Institute,New York City,United States

  • Institut Gustave-Roussy, Villejuif, France

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • MEI Pharma, Inc.,San Diego,United States

  • Medicine,University of Michigan,Ann Arbor,Vereinigte Staaten

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Univeristy of Bologna, Bologna, Italy

  • GenesisCare,Oxford,Verenigd Koninkrijk

  • The Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw,Warsaw,Poland

  • Medicine,University of Michigan,Ann Arbor,Vereinigte Staaten

  • GenesisCare,Oxford,Reino Unido

  • Vanderbilt University,Nashville,États-unis

  • Belfast Health and Social Care Trust

  • Kyowa Kirin Co.,Princeton,Vereinigte Staaten

  • GenesisCare,Oxford,Storbritannien

  • Regina Elena National Cancer Institute, Rome, Italy

  • Univeristy of Bologna, Bologna, Italy

  • Belfast Health and Social Care Trust, Belfast, United Kingdom

  • Kyowa Kirin Co.,Princeton,USA

  • Manchester Cancer Research Centre, Manchester, United Kingdom

  • GenesisCare,Oxford,United Kingdom

  • Univeristy of Bologna, Bologna, Italy

  • Regina Elena National Cancer Institute, Rome, Italy

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Manchester Cancer Research Centre,Manchester,Royaume-uni

  • MEI Pharma, Inc.,San Diego,Stati Uniti

  • Vanderbilt University Cancer Center,Nashville, TN,Verenigde Staten

  • MEI Pharma, Inc.,San Diego,United States

  • MEI Pharma, Inc.,San Diego,United States

  • University of Michigan Health System,Ann Arbor,États-unis

  • MEI Pharma, Inc.,San Diego,Estados Unidos

  • Istituto Scientifico Romagnolo per lo Studio...

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Univeristy of Bologna, Bologna, Italy

  • University of Michigan Health System, Ann Arbor, MI, United States,

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Manchester Cancer Research Centre, Manchester, United Kingdom

  • Kyowa Kirin Co.,Princeton,Vereinigte Staaten

  • Vanderbilt University Cancer Center,Nashville,Estados Unidos

  • Institut Gustave-Roussy, Villejuif, France

  • MEI Pharma, Inc., San Diego, CA

  • Maria Sklodow

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Univeristy of Bologna, Bologna, Italy

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Belfast Health and Social Care Trust, Belfast, United Kingdom

  • Belfast Health and Social Care Trust,Belfast,Royaume-uni

  • Univeristy of Bologna, Bologna, Italy

  • University of Bologna,Bologna,Италия

  • University of Michigan,Ann Arbor,Estados Unidos

  • University of Michigain Health System, Ann Arbor, MI

  • Institut Gustave-Roussy, Villejuif, France

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

  • Regina Elena National Cancer Institute, Rome, Italy

  • Belfast Health and Social Care Trust,Belfast,Verenigd Koninkrijk

  • Manchester Cancer Research Centre,Ma

  • Regina Elena National Cancer Institute, Rome, Italy

  • GenesisCare,Oxford,Соединённое Королевство

  • Vanderbilt University,Nashville,États-unis

  • Belfast Health and Social Care Trust, Belfast, United Kingdom

  • Vanderbilt University, TN

  • Institut Gustave-Roussy, Villejuif, France

  • MEI Pharma, Inc.,San Diego,États-unis

  • GenesisCare,Oxford,Reino Unido

Locations

  • United States

  • Poland

  • France

  • United Kingdom

  • Philippines

  • Spain

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • Protein Tyrosine Phosphatase, Non-Receptor Type 22

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT03768505

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved